ClinicalTrials.gg
RecruitingNCT05435222MSPP-MDDUpdated Mar 28, 2025

Evaluation of a Male-specific Psychotherapeutic Program for Major Depressive Disorders

An interventional study of Male-specific psychotherapeutic program (MSPP) and Cognitive beahvioral therapy (CBT) in Major Depressive Disorder, sponsored by Andreas Walther. Recruiting at 1 site in Switzerland. Open to male participants aged 25 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-03-28.

Sponsored by Andreas Walther · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
244
Allocation
Randomized
Ages
25 Years to 50 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Depressive Disorder, Major with a site in Switzerland — 7 open to participants now, 8 under way, none of them phase 3. Depressive Disorder, Major · Switzerland.

Planned enrollment
6th of 25
244 · median 60
Started
2023
the only one that year
No phase
18 of 30
6 open now
Registered
16th of 30
by date
Lead sponsor
1 of 30
Andreas Walther

Among the 30 studies in Depressive Disorder, Major with a site in Switzerland, this one is the 6th largest by planned enrollment of the 25 interventional ones that give a count, is the only one that started in 2023, is one of 18 with no phase, and was the 16th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

7 of the 30 studies in Depressive Disorder, Major with a site in Switzerland are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 25 Years to 50 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Depressive Disorder, Major with a site in Switzerland, or all of them as a file.
02

Study summary

This project aims to evaluate a male-specific psychotherapeutic program (MSPP) for MDD based on cognitive behavioral therapy (CBT). The primary goal is to test the superiority of the MSPP. This will be conducted in two groups of depressed men, namely eudonadal depressed men and hypogonadal depressed men receiving testosterone treatment (TT). In a randomized study design, the MSPP will be compared to a standard CBT and a waitlist control group, resulting in a total of six study groups. Both standardized psychotherapy programs will encompass 18 sessions delivered in a weekly manner, starting at study week 6 and continuing until study week 24. Aligned with the TT-related medical visits of the hypogonadal men, all participants will be followed up with clinical assessments and biosampling at weeks 0, 6, 15, 24, 36. In addition, a separate healthy control group will be examined, which will undergo only baseline assessments.

Read the detailed description

Background: Although women are twice as likely to suffer from major depressive disorder (MDD) than men, there are still over 100 million men affected by this condition worldwide. Unfortunately, men suffering from MDD seek mental health services about 30% less than women, leaving a large portion of men with unresolved mental health needs. This is reflected in 2-fold higher rates of alcohol use disorder and 4-fold higher rates of completed suicide amongst men, while MDD is considered a prime risk factor for both. A case is made for male-typical MDD phenotypes with differing symptom presentation often unrecognized by clinicians. Although cognitive behavioral therapy (CBT) represents an effective treatment for MDD, conformity to traditional masculinity norms based on stoicism, self-reliance, and restrictive emotionality often hinder men from engaging in psychotherapy. Therefore, a need to address this diagnostic and treatment gap emerges, while recent studies have identified a lack of male-specific psychotherapeutic programs (MSPP) that could persuade more men to take on psychotherapy based on a male-tailored nature, focusing on male-specific topics and being introduced in male-typical environments.

Method and study procedures: In total, 144 depressed men aged between 25 and 50 will be recruited. After Screening procedures, included participants are stratified by testosterone status (hypogoadal vs. eugonadal) and randomized to one of the conditions: MSPP, CBT, Waitlist. This results in six intervention groups (MSPP, CBT, Waitlist, MSPP+TT, CBT+TT, Waitlist+TT). Hypogonadal men will receive testosterone treatment administered at the Andrology-Urology Center (Uroviva). MSPP and CBT intervention groups will receive weekly therapy sessions for MDD over 18 weeks. All participants will be invited to a total of five examination appointments (weeks 0, 6, 15, 24, 36) at the psychological institute of the university of Zurich. In addition, a separate healthy control group will be examined, which will undergo only baseline assessments.

Expected results: Compared to the waitlist control groups, the treatment groups are expected to be more effective and efficacious (depression score reduction of ≥50%) at week 24 and at follow-up week 36. The MSPP, compared to CBT, is expected to show higher effectiveness and efficacy for depression symptoms, higher acceptability and a greater reduction of gender role conflict. In addition, it is expected that the initially hypogonadal men will have increased symptom improvement due to TT as compared to the eugonadal men in the parallel groups and that TT receiving men show an adjunct effect of added psychotherapy as compared to men in the waitlist.

03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
25 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male sex
  2. Age between 25 - 50 years
  3. German speaking
  4. Current major depression (assessed by SCID-5)
  5. as documented by signature

Exclusion criteria

Exclusion Criteria:

  1. Inability to give
  2. Prior hormonal (testosterone) treatment
  3. Prior mental health disorder
  4. Current or previous psychopharmacological treatment
  5. Current or previous psychological treatment for any psychological disorder

    • Exception for persistent depressive disorder (Dysthymia) and alcohol/substance use disorder of mild degree (SCID-5, 1 - 3 criteria met)
  6. Comorbidities of major depression with any other psychological disorder
  7. Severe physical disorder that requires priority treatment
  8. Any of the following physical conditions, particularly relevant in regard to testosterone treatment:

    • Diagnosed prostate cancer
    • Prostatic intraepithelial neoplasia (PIN)
    • Severe lower urinary tract symptoms
    • Erythrocytosis Sleep apnea, diagnosed but untreated
  9. Current treatment with:

    • Thyroid hormones
    • Finasteride
    • Antiepileptic drugs
    • Anabolic compounds
    • Hypnotic medication more than 2 nights/week for the treatment of insomnia
    • Long-acting benzodiazepines
    • Antipsychotic medication
    • Drugs that affect serum testosterone
  10. Genetic / hormonal disorders:

    • Klinefelter's syndrome
    • Cushing's disease
    • Addison's disease
    • Hashimoto Thyroiditis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
244 participants (estimated)

Study arms

  • Experimental
    male-specific psychotherapeutic program (MSPP)

    In this treatment group, eugonadal depressed men will receive the male-specific adjusted psychotherapy for depressive disorders (MSPP) based on cognitive behavioral principles in a single setting.

    Behavioral: Male-specific psychotherapeutic program (MSPP)

  • Active comparator
    cognitive behavioral therapy (CBT)

    In this treatment group, depressed men will receive standard cognitive behavioral psychotherapy for depressive disorders (CBT) in a single setting.

    Behavioral: Cognitive beahvioral therapy (CBT)

  • No intervention
    Waitlist

    The participants in the Waitlist group are required to complete a waiting period of 36 weeks prior receiving the MSPP. As an additional safety measure, participants will be monitored by means of three appointments at week 6, 10 and 14 with a study psychologist. Subsequently, monthly telephone calls at week 18, 22, 26, and 30 are conducted. During these appointments no intervention will occur, while a treatment relationship is to be established so that the patient can describe his specific life circumstances and report possible symptom exacerbations or suicidality.

  • Experimental
    male-specific psychotherapeutic program (MSPP) + testosterone treatment (TT)

    In this treatment group, hypogonadal depressed men will receive the male-specific adjusted psychotherapy for depressive disorders (MSPP) based on cognitive behavioral principles in a single setting. Further participants receive a standard testosterone replacement therapy consisting of testosterone undecanoate administered via deep intramuscular injection.

    Behavioral: Male-specific psychotherapeutic program (MSPP)

  • Active comparator
    cognitive behavioral therapy (CBT) + testosterone treatment (TT)

    In this treatment group, hypogonadal depressed men (blood testosterone ≤ 12.1 nmol/l) will receive standard cognitive behavioral psychotherapy for depressive disorders (CBT) in a single setting. Further participants receive a standard testosterone replacement therapy consisting of testosterone undecanoate administered via deep intramuscular injection.

    Behavioral: Cognitive beahvioral therapy (CBT)

  • No intervention
    Waitlist + testosterone treatment (TT)

    The participants in the Waitlist group are required to complete a waiting period of 36 weeks prior receiving the MSPP. As an additional safety measure, participants will be monitored by means of three appointments at week 6, 10 and 14 with a study psychologist. Subsequently, monthly telephone calls at week 18, 22, 26, and 30 are conducted. During these appointments no intervention will occur, while a treatment relationship is to be established so that the patient can describe his specific life circumstances and report possible symptom exacerbations or suicidality. Further participants receive a standard testosterone replacement therapy consisting of testosterone undecanoate administered via deep intramuscular injection.

Interventions

  • BehavioralMale-specific psychotherapeutic program (MSPP)

    The MSPP for MDD is designed to be used for the acute treatment of depression in men in 18 sessions over a period of 18 weeks. Therapy is delivered weekly with homework bridging every session. Central CBT elements (e.g. behavioral activation, cognitive restructuring) will be retained in MSPP. During implementation of typical CBT techniques, masculine role norms will be considered. One underlying topic will be the potential of multiple masculinities to coexist, being fluid and relational within one man, emphasizing positive aspects of masculinities compatible with psychotherapy for MDD.

  • BehavioralCognitive beahvioral therapy (CBT)

    This intervention consists of 18 sessions of manualized, standard cognitive behavioral therapy for major depression. Therapy is delivered weekly with homework bridging every session.

06

What researchers measure

Primary outcomes

  1. Change from baseline observer assessed depressive symptomatology to post treatment

    Observer assessed depressive symptomatology measured with the Hamilton Depression Rating Scale (HDRS-21)

    Time frame: baseline / 24 weeks

  2. Changes in the clinical symptomatology from baseline to post treatment

    Observer assessed clinical symptomatology measured with the Clinical Global impression Scale (CGI-S/I)

    Time frame: baseline / 24 weeks

  3. Change from baseline male typical depressive symptomatology to post treatment

    Self-reported male typical depression symptoms including externalizing behavior such as aggression, risk taking, or alcohol consumption measured with the Male Depression Risk Scale (MDRS-22)

    Time frame: baseline / 24 weeks

  4. Change from baseline self-reported depressive symptomatology to post treatment

    self-reported depressive symptomatology measured with the Beck Depression Inventory (BDI-II)

    Time frame: baseline / 24 weeks

  5. Changes in gender role conflict

    Self-reported symptoms of gender role conflict measured with the Gender Role Conflict Scale (GRCS-16)

    Time frame: baseline / 24 weeks

  6. Drop out

    Acceptability: Proportion of men who withdraw for any reason (dropout) will be recorded and if dropped out participants consent, a dropout interview will be conducted to examine the reasons for dropout.

    Time frame: at follow up week 36

  7. Achieved remission

    Proportion of participants, that achieved depressive symptom remission (assessed by structured clinical interview \[SCID-5-CV\] for DSM-V disorders)

    Time frame: post treatment week 24

  8. Changes in the therapeutic alliance quality

    Self reported working alliance quality with the therapist

    Time frame: week 6 / week 24

Secondary outcomes

  1. Skala Suizidales Erleben und Verhalten (SSEV-9)

    Self-reported suicidal experience and behavior

    Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36

  2. Suicide Cognitions Scales (SCS-18)

    Self-reported attitudes toward suicide

    Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36

  3. Problematic Pornography Consumption Scale (PPCS-18)

    Self-reported pornography use and problematic consumption

    Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36

  4. Alcohol Use Disorder Test 10 (AUDIT-10)

    Self-reported alcohol consumption symptomatology

    Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36

  5. International Index of Erectile Function 15 (IIEF-15)

    Self-reported sexual dysfunction and libido symptomatology

    Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36

  6. Perceived Stress Scale (PSS-10)

    Self-reported subjective stress

    Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36

  7. Generalized Anxiety Disorder (GAD-7)

    Self-reported general anxiety

    Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36

  8. Conformity Masculine Norms Inventory (CMNI-30)

    Self-reported conformity to traditional male role norms

    Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36

  9. Male Role Norms Inventory - Short Form (MRNI-SF-21)

    Self-reported socially learned male role norms

    Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36

  10. Precarious Manhood Beliefs Scale (PMB-4)

    Self-reported precarious manhood beliefs

    Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36

  11. Loneliness Scale (LS-20)

    Self-reported feeling of loneliness and social isolation

    Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36

  12. Self-Compassion Scale D (SCS-D 10)

    Self-reported Positive attitude towards oneself in difficult life situations

    Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36

  13. Emotion Regulation Questionnaire (ERQ-10)

    Self-reported tendency to re-evaluate / suppress emotions

    Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36

  14. General Belongingness Scale (GBS)

    Self-reported achieved belongingness

    Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36

  15. CIDI-Traumaliste (CIDI-T-12)

    Assessment of self-reported traumatic experiences over the life span

    Time frame: baseline / week 6 / post treatment week 24 / follow up week 36

  16. International Trauma Questionnaire (ITQ-18)

    Self-reported core symptoms of post-traumatic stress disorder and complex post-traumatic stress disorder

    Time frame: baseline / week 6 / post treatment week 24 / follow up week 36

  17. Agression Questionnaire Buss and Perry (AQ-BP)

    Self-reported anger and aggression symptomatology

    Time frame: baseline / week 6 / post treatment week 24 / follow up week 36

  18. Fragebogens zum Körperbild (FKB-6)

    Self-reported attitudes towards one's own and an ideal body image

    Time frame: baseline / week 6 / post treatment week 24 / follow up week 36

  19. Male Body Attitudes Scale-Revised (MBAS-R-15)

    Self-reported male-specific body (dis)satisfaction

    Time frame: baseline / week 6 / post treatment week 24 / follow up week 36

  20. Body Appreciation Scale 2 (BAS-2-10)

    Self-reported assessment of a positive body image

    Time frame: baseline / week 6 / post treatment week 24 / follow up week 36

  21. Stigma questionnaire (STIG-9)

    Self-reported experienced stigma for suffering from a mental illness

    Time frame: baseline / week 6 / post treatment week 24 / follow up week 36

  22. Self-stigma of seeking psychological help (SSOSH-10)

    Self-reported experienced stigma of seeking help

    Time frame: baseline / week 6 / post treatment week 24 / follow up week 36

  23. SHAME Questionnaire (SHAME-21)

    Self-reported physical, cognitive and existential shame

    Time frame: baseline / week 6 / post treatment week 24 / follow up week 36

  24. Test of Self-Conscious Affect (TOSCA-16)

    Assessment of susceptibility to guilt, shame, externalization, and unconcern (self-report questionnaire).

    Time frame: baseline / week 6 / post treatment week 24 / follow up week 36

  25. Toronto Alexithymia Scale (TAS-20)

    Self-reported difficulty identifying and describing emotions

    Time frame: baseline / week 6 / post treatment week 24 / follow up week 36

  26. Multidimensional Self-Concept Scale (MSCS)

    Self-reported self-concept (self-worth)

    Time frame: baseline / week 6 / post treatment week 24 / follow up week 36

  27. Arnett Inventory of Sensation Seeking (AISS-20)

    Self-reported seeking of intense experiences including risky behavior

    Time frame: baseline / week 6 / post treatment week 24 / follow up week 36

  28. Need to Belong Scale (NTBS-10)

    Self-reported motivation to be accepted by others and avoidance of rejection by others

    Time frame: baseline / week 6 / post treatment week 24 / follow up week 36

Other outcomes

  1. Body composition

    Body composition is determined by using bioelectrical impedance analysis (BIA)

    Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36

  2. Blood testosteron

    Blood samples are collected at each study visit to assess blood testosterone

    Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36

  3. Hair testosterone

    Hair samples are collected at each study visit to assess hair testosterone

    Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36

  4. Grip strength

    Grip strength will be assessed with a basic hydraulic hand dynamometer at each study visit

    Time frame: baseline / week 6 / week 15 / post treatment week 24 / follow up week 36

07

Study locations

1 of 1 sites recruiting
  • Ambulatory for Cognitive Behavioral Therapy and Behavioral Medicine of the University of Zurich
    Zürich, 8032, Switzerland
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Oct 2025, 30 months after the start.

Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 30 months is below that.

Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2020
First posted
Jun 28, 2022
StartActual
Mar 15, 2023
Primary completionEst.
Oct 1, 2025
CompletionEst.
Oct 31, 2025
Last update
Mar 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05435222
Lead sponsor
Andreas Walther
Responsible party
Andreas Walther (Dr. phil., University of Zurich) — Sponsor-investigator
First posted
Jun 28, 2022
Start date
Mar 15, 2023
Primary completion
Oct 1, 2025 (estimated)
Completion
Oct 31, 2025 (estimated)
Last update
Mar 28, 2025

Study contacts

Andreas Walther, PhD
Contact
a.walther@psychologie.uzh.ch
+41 78 307 18 16
Ulrike Ehlert, Professor
Contact
u.ehlert@psychologie.uzh.ch
+41 44 635 73 50
Andreas Walther, PhD
principal investigator · University of Zurich

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion